Reference is made to the stock exchange release from earlier today, 13[th]
January 2025, regarding new funding, including a convertible loan facility of
NOK 15 million.

The following primary insiders, or closely related companies to primary
insiders, are a part of the total investor consortium:

  · Ronja Capital Investment AS, a company closely related to Board Member Tore
Tønseth, NOK 3,0 million
  · Vartdal Holding AS, a company closely related to Board Member Jan Endre
Vartdal, NOK 1,0 million
  · Brødrene Vartdal AS, a company closely related to Board Member Jan Endre
Vartdal, NOK 1,0 million
  · Ajea Invest AS, a company closely related to Board Member Asbjørn
Solevågseide, NOK 0,5 million
  · Eros AS, a company closely related to Board Member Per Magne Eggesbø, NOK
0,6 million
  · Siglar AS, a company closely related to Chairman of the Board Harald Nordal,
NOK 0,15 million
  · Clu Invest AS, a company closely related to CEO Christer L. Valderhaug, NOK
0,1 million
  · Runhild Gammelsæter, Medical Director, NOK 0,05 million

This information is subject to the disclosure requirements pursuant to
Regulation EU 596/2014 (MAR) article 19 and the Norwegian Securities Trading Act
§ 5-12.

For more information, please contact:

Jone R. Slinning

CFO

Phone: +47 948 75 469

E-mail: jone@arctic-bioscience.com

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing
pharmaceutical and nutraceutical products based on unique bioactive marine
compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being
developed for treatment of patients with mild-to-moderate psoriasis. This is a
large patient group in need of new effective medicines with beneficial safety
profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as
well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and
highly relevant background.

